Free Trial
NYSE:ENZ

Enzo Biochem (ENZ) Stock Price, News & Analysis

Enzo Biochem logo
$0.31 +0.02 (+6.21%)
As of 02:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Enzo Biochem Stock (NYSE:ENZ)

Key Stats

Today's Range
$0.26
$0.33
50-Day Range
$0.29
$0.65
52-Week Range
$0.25
$1.28
Volume
343,926 shs
Average Volume
131,608 shs
Market Capitalization
$16.14 million
P/E Ratio
N/A
Dividend Yield
129.87%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Remove Ads
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

Enzo Biochem to delist stock from NYSE
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Enzo Biochem reports Q2 revenue $7.3M vs. $6.2M in Q1
See More Headlines

ENZ Stock Analysis - Frequently Asked Questions

Enzo Biochem's stock was trading at $0.7143 at the beginning of the year. Since then, ENZ shares have decreased by 57.0% and is now trading at $0.3070.
View the best growth stocks for 2025 here
.

Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings data on Monday, March, 17th. The medical research company reported ($0.02) EPS for the quarter. The medical research company earned $7.33 million during the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 7.96% and a negative net margin of 75.34%.

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzo Biochem investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and OneLife Technologies (OLMM).

Company Calendar

Last Earnings
3/17/2025
Today
4/07/2025
Next Earnings (Estimated)
6/11/2025
Fiscal Year End
7/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NYSE:ENZ
Employees
520
Year Founded
1976

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-26,080,000.00
Pretax Margin
-23.79%

Debt

Sales & Book Value

Annual Sales
$29.09 million
Price / Cash Flow
N/A
Book Value
$1.09 per share
Price / Book
0.29

Miscellaneous

Free Float
46,288,000
Market Cap
$16.72 million
Optionable
Optionable
Beta
1.19

Social Links

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NYSE:ENZ) was last updated on 4/7/2025 by MarketBeat.com Staff
From Our Partners